Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center, Open-label, Single Dosing, Dose-Ascending, Phase 1 Study to Evaluate the Safety and Tolerability of KINE-101 in Patients With CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) Refractory to Corticosteroid Treatment

NCT07343310 is registered in ClinicalTrials.gov with Kine Sciences Co., Ltd. as lead sponsor.

NCT NCT07343310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07343310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center, Open-label, Single Dosing, Dose-Ascending, Phase 1 Study to Evaluate the Safety and Tolerability of KINE-101 in Patients With CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) Refractory to Corticosteroid Treatment
Lead sponsor
Kine Sciences Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 27, 2024
Completion date
April 14, 2025
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cidp - chronic inflammatory demyelinating polyneuropathy